RxDoctor Payments Data

Kristen Jordan

Family · South Miami, FLNPI 1417492729

Payments from drug & device makers

$16,911in general payments, 2019–2025

Across 982 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Johnson & Johnson$2K
  • UCB, Inc.$2K
  • AbbVie$2K
  • Novartis$2K
  • Mallinckrodt Hospital Products Inc.$1K
  • plus $5K from 22 others

What the payments were for

  • Food & beverage$16,832100%
  • Education$790%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,911 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$280,356
Medicare patients
93
Services billed
17,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Unoready PenSecukinumab63$558,333
Humira(Cf) PenAdalimumab35$327,277
Orencia ClickjectAbatacept55$310,408
TremfyaGuselkumab16$220,040
Xeljanz XrTofacitinib Citrate24$160,976
Enbrel SureclickEtanercept18$142,857
OrenciaAbatacept/Maltose30$136,879
Simponi AriaGolimumab13$116,944
OrenciaAbatacept16$91,592
KevzaraSarilumab15$65,862
TymlosAbaloparatide14$37,252
ProliaDenosumab17$29,299
RasuvoMethotrexate/Pf25$16,535
Colchicine141$9,840
Mycophenolate Mofetil68$7,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya, Simponi Aria$1,918$336,98329 claims
E.r. Squibb & Sons, L.L.C.Orencia, Orencia$281$228,47146 claims
SanofiKevzara$106$65,86215 claims
Radius Health, Inc.Tymlos$398$37,25214 claims
AmgenProlia$3,408$29,29917 claims
Scilex Pharmaceuticals Inc.Colchicine$120$9,840141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →